Versor Investments LP Reduces Stock Holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Versor Investments LP lowered its position in Horizon Therapeutics Public Limited (NASDAQ:HZNPFree Report) by 36.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 126,299 shares of the biopharmaceutical company’s stock after selling 70,928 shares during the quarter. Horizon Therapeutics Public accounts for approximately 2.2% of Versor Investments LP’s holdings, making the stock its 13th biggest holding. Versor Investments LP owned 0.06% of Horizon Therapeutics Public worth $12,990,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Bank of America Corp DE increased its position in Horizon Therapeutics Public by 19.5% during the 4th quarter. Bank of America Corp DE now owns 1,506,499 shares of the biopharmaceutical company’s stock worth $171,440,000 after purchasing an additional 245,610 shares in the last quarter. Los Angeles Capital Management LLC increased its position in Horizon Therapeutics Public by 2.4% during the 1st quarter. Los Angeles Capital Management LLC now owns 149,319 shares of the biopharmaceutical company’s stock worth $16,297,000 after purchasing an additional 3,507 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Horizon Therapeutics Public by 34.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 3,094 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 792 shares in the last quarter. Ethic Inc. purchased a new stake in Horizon Therapeutics Public during the 1st quarter worth about $486,000. Finally, Treasurer of the State of North Carolina grew its holdings in Horizon Therapeutics Public by 0.5% in the 1st quarter. Treasurer of the State of North Carolina now owns 101,734 shares of the biopharmaceutical company’s stock valued at $11,103,000 after buying an additional 479 shares during the period. Hedge funds and other institutional investors own 80.37% of the company’s stock.

Analyst Ratings Changes

HZNP has been the subject of several recent analyst reports. Jefferies Financial Group cut Horizon Therapeutics Public from a “buy” rating to a “hold” rating in a report on Friday, September 1st. StockNews.com cut Horizon Therapeutics Public from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 5th. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $110.71.

Check Out Our Latest Research Report on Horizon Therapeutics Public

Horizon Therapeutics Public Stock Down 0.6 %

Horizon Therapeutics Public stock traded down $0.65 during midday trading on Monday, hitting $114.77. 6,259,816 shares of the company were exchanged, compared to its average volume of 2,341,905. The company’s fifty day moving average price is $105.11 and its 200-day moving average price is $106.06. The company has a market cap of $26.28 billion, a PE ratio of 61.72, a price-to-earnings-growth ratio of 3.51 and a beta of 1.05. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.27 and a quick ratio of 4.09. Horizon Therapeutics Public Limited has a fifty-two week low of $60.03 and a fifty-two week high of $115.70.

Horizon Therapeutics Public (NASDAQ:HZNPGet Free Report) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.12 by $0.08. The firm had revenue of $945.00 million for the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a return on equity of 20.46% and a net margin of 12.02%. Horizon Therapeutics Public’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.07 EPS. On average, research analysts predict that Horizon Therapeutics Public Limited will post 4.7 EPS for the current fiscal year.

Horizon Therapeutics Public Profile

(Free Report)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.

Featured Stories

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNPFree Report).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.